News Releases | Upcoming Events | Webcast/Presentation Archive

View printer-friendly version << Back

Masimo Reports Third Quarter 2015 Financial Results and Announces New Five Million Share Repurchase Plan

11/05/15

Q3 2015 Highlights (compared to Q3 2014):

  • Total revenue, including royalties, rose 5.9% to $152.6 million
  • Product revenue rose 5.4% to $144.6 million
  • Masimo rainbow® revenue rose 29.7% to $17.1 million
  • SET® and rainbow® SET® units shipments were 45,800
  • GAAP net income of $19.3 million, or $0.36 per diluted share versus $14.9 million or $0.27 per diluted share in the year-ago period
  • Non-GAAP net income of $21.3 million, or $0.40 per diluted share versus $15.2 million or $0.28 per diluted share in the year-ago period

IRVINE, Calif.--(BUSINESS WIRE)--Nov. 5, 2015-- Masimo (NASDAQ: MASI) today announced its financial results for the third quarter ended October 3, 2015.

Third quarter 2015 product revenues rose 5.4% to $144.6 million, compared to $137.1 million for the third quarter of fiscal year 2014, and total revenue, including royalties, rose 5.9% to $152.6 million, up from $144.1 million for the third quarter of fiscal year 2014. The unfavorable effect of foreign currency movements reduced third quarter product revenues by approximately $4.8 million.

The company’s worldwide direct product revenue in the third quarter of 2015 rose by 3.5% compared to the same period in 2014 and represented 84.7% of product revenue. OEM sales, which accounted for 16.9% of product revenue, rose by 16.0% to $24.4 million in the third quarter of 2015 compared to the same period in 2014. Revenue from sales of Masimo rainbow® products rose by 29.7% to $17.1 million in the third quarter of 2015, compared to the same period in 2014.

GAAP net income for the third quarter of 2015 was $19.3 million, or $0.36 per diluted share, compared to GAAP net income of $14.9 million, or $0.27 per diluted share, in the third quarter of 2014. Non-GAAP net income for the third quarter was $21.3 million, or $0.40 per diluted share, versus non-GAAP net income of $15.2 million or $0.28 per diluted share in the year-ago period. During the third quarter of 2015, the company shipped 45,800 SET® pulse oximetry and rainbow® Pulse CO-Oximetry units, excluding handheld units. Masimo estimates its worldwide installed base as of October 3, 2015 to be 1,390,000 units, up 7.8% from 1,289,000 units as of September 27, 2014.

Joe Kiani, Chairman and Chief Executive Officer of Masimo, said, “Our third quarter results reflect the continued demand for our SET® Pulse Oximetry technology and our emerging rainbow® SET® Pulse CO-Oximetry technology. We are happy to be able to report record quarterly driver shipments and rainbow revenues, and another quarter of strong year-over-year earnings growth. Our underlying technology strength, along with our continued focus on value engineering and expense management, continue to make us confident about the financial leverage in our business model.”

During the nine month period ended October 3, 2015, the company generated $53.5 million in cash from operations and as of October 3, 2015, total cash and cash investments were $103.6 million compared to $134.5 million as of January 3, 2015. Also, during the nine month period ended October 3, 2015, the company repurchased approximately 3.5 million shares of stock for $130.2 million, including approximately 1.2 million shares in the quarter ended October 3, 2015 for $48.5 million. These repurchases complete the original 9.0 million share stock repurchase plan authorized by the Board in 2013. Today, Masimo is also announcing the Board’s authorization of a new 5.0 million share stock repurchase plan.

2015 Financial Guidance

Masimo today is updating its 2015 financial guidance. Masimo now expects fiscal 2015 total revenues to be approximately $627 million, up from $621 million. Total fiscal 2015 product revenues are now expected to be approximately $597 million, up from $592 million, while royalty revenues are now expected to be $30 million, up from $29 million. Masimo now also expects its fiscal 2015 GAAP earnings per diluted share to be $1.49, up from $1.43 and expects non-GAAP earnings per diluted share to be approximately $1.67, up from $1.61. Masimo will provide additional financial information during the conference call today. Each of the components of Masimo’s guidance set forth above is an estimate only and actual performance could differ.

Conference Call

Masimo will hold a conference call today at 1:30 p.m. PT (4:30 p.m. ET) to discuss the results. A live webcast of the call will be available online from the investor relations page of the company’s website at www.masimo.com. The dial-in numbers are (888) 520-7182 for domestic callers and +1 (706) 758-3929 for international callers. The reservation code for both dial-in numbers is 64862474. After the live webcast, the call will be available on Masimo’s website through December 4, 2015. In addition, a telephonic replay of the call will be available through November 19, 2015. The replay dial-in numbers are (800) 585-8367 for domestic callers and +1 (855) 859-2056 for international callers. Please use reservation code 64862474.

About Masimo

Masimo (NASDAQ: MASI) is the global leader in innovative noninvasive monitoring technologies that significantly improve patient care-helping solve “unsolvable” problems. In 1995, the company debuted Measure-Through-Motion and Low-Perfusion pulse oximetry, known as Masimo SET®, which virtually eliminated false alarms and increased pulse oximetry’s ability to detect life-threatening events. More than 100 independent and objective studies have shown that Masimo SET® outperforms other pulse oximetry technologies, even under the most challenging clinical conditions, including patient motion and low peripheral perfusion. In 2005, Masimo introduced rainbow SET® Pulse CO-Oximetry technology, allowing noninvasive and continuous monitoring of blood constituents that previously could only be measured invasively, including total hemoglobin (SpHb®), oxygen content (SpOC), carboxyhemoglobin (SpCO®), methemoglobin (SpMet®), and Pleth Variability Index (PVI®), in addition to SpO2, pulse rate, and perfusion index (PI). Additional information about Masimo and its products may be found at www.masimo.com.

Forward-Looking Statements

All statements other than statements of historical facts included in this press release that address activities, events or developments that we expect, believe or anticipate will or may occur in the future are forward-looking statements including, in particular, the statements about our expectations for full fiscal year 2015 total and product revenues and GAAP and non-GAAP earnings per diluted share; demand for our products; anticipated revenue and earnings growth; our financial condition, results of operations and business generally; expectations regarding our ability to design and deliver innovative new noninvasive technologies and reduce the cost of care; and demand for our technologies. These forward-looking statements are based on management’s current expectations and beliefs and are subject to uncertainties and factors, all of which are difficult to predict and many of which are beyond our control and could cause actual results to differ materially and adversely from those described in the forward-looking statements. These risks include, but are not limited to, those related to: our dependence on Masimo SET® and Masimo rainbow® SET® products and technologies for substantially all of our revenue; any failure in protecting our intellectual property exposure to competitors’ assertions of intellectual property claims; the highly competitive nature of the markets in which we sell our products and technologies; any failure to continue developing innovative products and technologies; the lack of acceptance of any of our current or future products and technologies; obtaining regulatory approval of our current and future products and technologies; the risk that the implementation of our international realignment will not continue to produce anticipated operational and financial benefits, including a continued lower effective tax rate; the loss of our customers; the failure to retain and recruit senior management; product liability claims exposure; a failure to obtain expected returns from the amount of intangible assets we have recorded; the maintenance of our brand; the amount and type of equity awards that we may grant to employees and service providers in the future; our ongoing litigation and related matters; and other factors discussed in the “Risk Factors” section of our most recent periodic reports filed with the Securities and Exchange Commission (“SEC”), including our most recent Form 10-K and Form 10-Q, all of which you may obtain for free on the SEC’s website at www.sec.gov. Although we believe that the expectations reflected in our forward-looking statements are reasonable, we do not know whether our expectations will prove correct. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof, even if subsequently made available by us on our website or otherwise. We do not undertake any obligation to update, amend or clarify these forward-looking statements, whether as a result of new information, future events or otherwise, except as may be required under applicable securities laws.

Masimo, SET, Signal Extraction Technology, Improving Patient Outcome and Reducing Cost of Care... by Taking Noninvasive Monitoring to New Sites and Applications, rainbow, SpHb, SpOC, SpCO, SpMet, PVI are trademarks or registered trademarks of Masimo Corporation

MASIMO CORPORATION
CONDENSED CONSOLIDATED BALANCE SHEETS
(unaudited, in thousands)
 
  October 3,   January 3,
  2015     2015  
ASSETS
Current assets
Cash and cash equivalents $ 103,581 $ 134,453
Accounts receivable, net of allowance for doubtful accounts 75,465 71,017
Inventories 73,311 69,718
Prepaid income taxes 5,420 417
Other current assets 21,710 21,471
Deferred tax assets   18,062     18,065  
Total current assets 297,549 315,141
Deferred cost of goods sold 67,891 67,485
Property and equipment, net 128,569 101,952
Intangible assets, net 27,883 27,771
Goodwill 20,452 20,979
Deferred tax assets 24,124 24,193
Other assets   11,318     7,485  
Total assets $ 577,786   $ 565,006  
LIABILITIES AND EQUITY
Current liabilities
Accounts payable $ 28,735 $ 38,045
Accrued compensation 31,734 33,600
Accrued liabilities 24,096 24,541
Income taxes payable 2,481 6,562
Deferred revenue 24,647 21,067
Current portion of capital lease obligations   80     79  
Total current liabilities 111,773 123,894
Deferred revenue 337 453
Long term debt 190,100 125,145
Other liabilities   7,342     7,773  
Total liabilities 309,552 257,265
Commitments and contingencies
Equity
Masimo Corporation stockholders’ equity:
Common stock 50 52
Treasury stock (316,063 ) (185,906 )
Additional paid-in capital 325,128 288,686
Accumulated other comprehensive loss (4,339 ) (2,093 )
Retained earnings   264,459     205,260  
Total Masimo Corporation stockholders’ equity 269,235 305,999
Noncontrolling interest   (1,001 )   1,742  
Total equity   268,234     307,741  
Total liabilities and equity $ 577,786   $ 565,006  
 
MASIMO CORPORATION
CONDENSED CONSOLIDATED STATEMENTS OF INCOME
(unaudited, in thousands, except per share amounts)
 
  Three Months Ended   Nine Months Ended
October 3,   September 27, October 3,   September 27,
  2015     2014     2015     2014  
Revenue:
Product $ 144,603 $ 137,142 $ 439,572 $ 402,868
Royalty   7,972     6,976     23,266     21,988  
Total revenue 152,575 144,118 462,838 424,856
Cost of goods sold   50,343     47,894     154,600     143,236  
Gross profit 102,232 96,224 308,238 281,620
Operating expenses:
Selling, general and administrative 59,607 62,064 182,072 179,533
Research and development 14,485 14,213 42,808 41,552
Litigation award and defense costs       (2,321 )       (10,331 )
Total operating expenses   74,092     73,956     224,880     210,754  
Operating income 28,140 22,268 83,358 70,866
Non-operating (expense) income   (1,050 )   (566 )   (2,022 )   (43 )
Income before provision for income taxes 27,090 21,702 81,336 70,823
Provision for income taxes   9,161     5,568     24,889     18,246  
Net income including noncontrolling interest 17,929 16,134 56,447 52,577
Net loss (income) attributable to the noncontrolling interest   1,396     (1,271 )   2,752     (1,280 )
Net income attributable to Masimo Corporation stockholders   19,325     14,863     59,199     51,297  
 
Net income per share attributable to Masimo Corporation stockholders:
Basic $ 0.38   $ 0.28   $ 1.15   $ 0.92  
Diluted $ 0.36   $ 0.27   $ 1.10   $ 0.91  
 
Weighted-average shares used in per share calculations:
Basic   50,974     53,988     51,653     55,521  
Diluted   53,686     54,618     53,946     56,381  
 

The following table presents details of the share-based compensation expense that is included in each functional line item in the condensed consolidated statements of income (in thousands):

 
Three Months Ended Nine Months Ended
October 3, September 27, October 3, September 27,
  2015     2014     2015     2014  
Cost of goods sold $ 79 $ 90 $ 270 $ 333
Selling, general and administrative 1,985 2,220 6,052 6,308
Research and development   639     265     1,810     1,143  
Total $ 2,703   $ 2,575   $ 8,132   $ 7,784  
 
MASIMO CORPORATION
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(unaudited, in thousands)
 
  Nine Months Ended
October 3,   September 27,
2015 2014
Cash flows from operating activities:
Net income including noncontrolling interest $ 56,447 $ 52,577
Adjustments to reconcile net income including noncontrolling interest to net cash provided by operating activities:
Depreciation and amortization 11,603 9,481
Share-based compensation 8,132 7,784
Loss on disposal of property and equipment 22 2
Provision for doubtful accounts 506 211
Provision for deferred income taxes 2,926
Income tax benefit from exercise of stock options granted prior to January 1, 2006 2,006 49
Excess tax (benefit) deficit from share-based compensation arrangements (1,837 ) 74
Changes in operating assets and liabilities:
(Increase) decrease in accounts receivable (5,048 ) 3,198
Increase in inventories (3,755 ) (6,306 )
Increase in deferred cost of goods sold (528 ) (3,580 )
Increase in prepaid income taxes (5,003 ) (685 )
Increase in other assets (4,140 ) (4,793 )
Decrease in accounts payable (4,179 ) (1,609 )
(Decrease) increase in accrued compensation (1,436 ) 1,181
(Decrease) increase in accrued liabilities (276 ) 5,446
(Decrease) increase in income tax payable (2,212 ) 558
Increase in deferred revenue 3,465 445
Decrease in other liabilities   (272 )   (136 )
Net cash provided by operating activities   53,495     66,823  
Cash flows from investing activities:
Purchases of property and equipment, net (40,520 ) (66,847 )
Increase in intangible assets   (3,085 )   (2,779 )
Net cash used in investing activities   (43,605 )   (69,626 )
Cash flows from financing activities:
Borrowings under line of credit 107,500 125,000
Repayments on line of credit (42,500 )
Debt issuance costs (143 )
Repayments of capital lease obligations (81 ) (105 )
Proceeds from issuance of common stock 24,942 2,687
Payroll tax withholdings on behalf of employees for stock options (472 )
Excess tax benefit (deficit) from share-based compensation arrangements 1,837 (74 )
Repurchases of common stock (130,157 ) (98,676 )
Issuance (repurchases) of equity by noncontrolling interest, net of equity issued   4     (38 )
Net cash (used in) provided by financing activities   (38,927 )   28,651  
Effect of foreign currency exchange rates on cash   (1,835 )   (2,326 )
Net (decrease) increase in cash and cash equivalents (30,872 ) 23,522
Cash and cash equivalents at beginning of period   134,453     95,466  
Cash and cash equivalents at end of period $ 103,581   $ 118,988  
 
MASIMO CORPORATION

SUPPLEMENTAL NON-GAAP INFORMATION

(unaudited in thousands, except percentages and per share amounts)
 

RECONCILIATION OF GAAP NET INCOME TO NON-GAAP NET INCOME ATTRIBUTABLE TO MASIMO SHAREHOLDERS:

       
Three Months Ended Nine Months Ended
October 3, September 27, October 3, September 27,
2015 2014 2015 2014
GAAP net income attributable to Masimo Corporation stockholders $ 19,325 $ 14,863 $ 59,199 $ 51,297
 
Non-GAAP adjustments:

Constant currency F/X adjustments:

Product revenue 4,769 14,486
Cost of goods sold (1,262 ) (3,159 )
Operating expenses (1,724 ) (5,648 )
Non-operating income

 

  (154 )       673      
Subtotal - Constant currency F/X adjustments 1,629 6,352
 

Amortization of acquisition-related intangible assets:

Cost of goods sold 114 114 343 343
Operating expenses   274     274     821     821  
Subtotal - Amortization of acquisition-related intangible assets 388 388 1,164 1,164
 

Litigation awards, damages and defense costs:

Operating expenses (2,321 ) (10,331 )
Noncontrolling interest       2,321         2,321  
Subtotal - Litigation awards, damages and defense costs (8,010 )
 
Net tax impact of above items (24 ) (88 ) (149 ) 2,813
       
Total non-GAAP adjustments   1,993     300     7,367     (4,033 )
 
Non-GAAP net income attributable to Masimo Corporation stockholders $ 21,318   $ 15,163   $ 66,566   $ 47,264  
 
Net income per diluted share attributable to Masimo Corporation stockholders:
GAAP net income per diluted share $ 0.36 $ 0.27 $ 1.10 $ 0.91
Non-GAAP Adjustments per diluted share   0.04     0.01     0.13     (0.07 )
Non-GAAP net income per diluted share $ 0.40   $ 0.28   $ 1.23   $ 0.84  
 

RECONCILIATION OF GAAP TO NON-GAAP EPS GUIDANCE:

 
Fiscal Year
Ending
January 2,
  2016  
GAAP EPS guidance $ 1.49
Constant currency F/X adjustments 0.15
Amortization of acquisition-related intangible assets 0.03
Litigation awards, damages and defense costs
Net tax impact of above items    
Total non-GAAP EPS adjustments   0.18  
Non-GAAP EPS guidance $ 1.67  

Non-GAAP Financial Measures

The non-GAAP financial measures contained herein are a supplement to the corresponding financial measures prepared in accordance with U.S. generally accepted accounting principles (GAAP). The non-GAAP financial measures presented exclude the items summarized in the above table that are more fully described below. Management believes that adjustments for these items assist investors in making comparisons of period-to-period operating results and that these items are not indicative of the company’s on-going core operating performance. These non-GAAP financial measures have certain limitations in that they do not reflect all of the costs associated with the operations of the company’s business as determined in accordance with GAAP. Therefore, investors should consider non-GAAP financial measures in addition to, and not as a substitute for, or as superior to, measures of financial performance prepared in accordance with GAAP. The non-GAAP financial measures presented by the company may be different from the non-GAAP financial measures used by other companies.

The company has presented the following non-GAAP measures on a basis consistent with its historical presentation, to assist investors in understanding the company’s core net operating results on an on-going basis: (i) non-GAAP net income attributable to Masimo Corporation stockholders, (ii) non-GAAP product revenue, (iii) non-GAAP gross profit, (iv) non-GAAP operating expenses, (v) non-GAAP non-operating income (expense), (vi) non-GAAP noncontrolling interest, and (vii) non-GAAP net income per diluted share attributable to Masimo Corporation stockholders. These non-GAAP financial measures may also assist investors in making comparisons of the company’s core operating results with those of other companies. Management believes non-GAAP product revenue, non-GAAP gross profit, non-GAAP net income attributable to Masimo Corporation stockholders and non-GAAP net income per diluted share attributable to Masimo Corporation stockholders are important measures in the evaluation of the Company’s performance and uses these measures to better understand and evaluate our business.

The non-GAAP financial measures reflect adjustments for the following items, as well as the related income tax effects thereof:

Constant currency F/X adjustments. Some of our sales agreements with foreign customers provide for payment in currencies other than the U.S. Dollar. Similarly, certain of our product costs and operating expenses, and the related balance sheet payables and accruals, are denominated in foreign currencies other than the U.S. Dollar. These foreign currency revenues, costs and expenses, receivables, payables and accruals, when converted into U.S. Dollars, can vary significantly from period to period depending on the average and quarter-end exchange rates during a respective period. We believe that comparing these foreign currency denominated revenues, costs and expenses, receivables, payables and accruals by holding the exchange rates constant with the prior year period is useful to management and investors in evaluating the performance of our ongoing operations on a period-to-period basis. We anticipate that fluctuations in foreign exchange rates and these related constant currency and other foreign exchange adjustments will continue to occur in future periods.

Amortization of acquisition-related intangibles. Amortization of intangibles generally represents costs incurred by an acquired company or other third party to build value prior to our acquisition of the intangible assets. As such, it is effectively part of the transaction costs of the acquisition rather than ongoing costs of operating our core business. As a result, we believe that exclusion of these costs in presenting non-GAAP financial measures provides management and investors a more effective means of evaluating its historical performance and projected costs and the potential for realizing cost efficiencies within our core business. Amortization of intangibles will recur in future periods.

Litigation awards, damages and defense costs. In connection with litigation proceedings arising in the course of our business, we have previously recorded expenses as a defendant in such proceedings in the form of damages and directly-related legal fees, as well as reversals of such damages and directly-related legal fee expenses upon a court vacating a prior award against us. In addition, we have also previously recorded recoveries of damages and directly-related legal fees as a plaintiff in litigation proceedings. We believe that exclusion of these expenses, expense reversals and recoveries is useful to management and investors in evaluating the performance of our ongoing operations on a period-to-period basis. In this regard, we note that these expenses, expense reversals and recoveries are generally unrelated to our core business and/or infrequent in nature.

Reconciliations between the GAAP and non-GAAP amounts for each financial statement line item are as follows:

RECONCILIATION OF GAAP PRODUCT REVENUE TO NON-GAAP PRODUCT REVENUE:

  Three Months Ended   Nine Months Ended
October 3,   September 27, October 3,   September 27,
2015 2014 2015 2014
GAAP product revenue $ 144,603 $ 137,142 $ 439,572 $ 402,868
 
Non-GAAP adjustments
Constant currency F/X adjustments   4,769         14,486      
Total non-GAAP product revenue adjustments   4,769         14,486      
 
Non-GAAP product revenue $ 149,372   $ 137,142   $ 454,058   $ 402,868  
 

RECONCILIATION OF GAAP GROSS PROFIT TO NON-GAAP GROSS PROFIT:

Three Months Ended Nine Months Ended
October 3, September 27, October 3, September 27,
2015 2014 2015 2014
GAAP gross profit $ 102,232 $ 96,224 $ 308,238 $ 281,620
GAAP product gross profit % 65.2 % 65.1 % 64.8 % 64.4 %
GAAP total gross profit % 67.0 % 66.8 % 66.6 % 66.3 %
 
Non-GAAP adjustments
Constant currency F/X adjustments 3,507 11,327
Amortization of acquisition-related intangible assets   114     114     343     343  
Total non-GAAP gross profit adjustments   3,621     114     11,670     343  
 
Non-GAAP gross profit $ 105,853   $ 96,338   $ 319,908   $ 281,963  
Non-GAAP product gross profit % 65.5 % 65.2 % 65.3 % 64.5 %
Non-GAAP total gross profit % 67.3 % 66.8 % 67.0 % 66.4 %
 

RECONCILIATION OF GAAP OPERATING EXPENSES TO NON-GAAP OPERATING EXPENSES:

Three Months Ended Nine Months Ended
October 3, September 27, October 3, September 27,
2015 2014 2015 2014
GAAP operating expenses $ 74,092 $ 73,956 $ 224,880 $ 210,754
 
Non-GAAP adjustments
Constant currency F/X adjustments 1,724 5,648
Amortization of acquisition-related intangible assets (274 ) (274 ) (821 ) (821 )
Litigation awards, damages and defense costs       2,321         10,331  
Total non-GAAP operating expenses adjustments   1,450     2,047     4,827     9,510  
 
Non-GAAP operating expenses $ 75,542   $ 76,003   $ 229,707   $ 220,264  
 

RECONCILIATION OF GAAP NON-OPERATING INCOME TO NON-GAAP NON-OPERATING INCOME:

  Three Months Ended   Nine Months Ended
October 3,   September 27, October 3,   September 27,
2015 2014 2015 2014
GAAP non-operating income (expense) (1,050 ) (566 ) (2,022 ) (43 )
 
Non-GAAP adjustments
Constant currency F/X adjustments   (154 )       673      
Total non-GAAP non-operating income adjustments   (154 )       673      
 
Non-GAAP non-operating income (expense) $ (1,204 ) $ (566 ) $ (1,349 ) $ (43 )
 

RECONCILIATION OF GAAP NONCONTROLLING INTEREST TO NON-GAAP NONCONTROLLING INTEREST:

Three Months Ended Nine Months Ended
October 3, September 27, October 3, September 27,
2015 2014 2015 2014
GAAP noncontrolling interest 1,396 (1,271 ) 2,752 (1,280 )
 
Non-GAAP adjustments
Litigation awards, damages and defense costs (2,321 ) (2,321 )
Tax impact of above items       (341 )       (341 )
Total non-GAAP noncontrolling interest adjustments       (2,662 )       (2,662 )
 
Non-GAAP noncontrolling interest $ 1,396   $ (3,933 ) $ 2,752   $ (3,942 )
 

RECONCILIATION OF GAAP NET INCOME PER DILUTED SHARE TO NON-GAAP NET INCOME PER DILUTED SHARE:

Three Months Ended Nine Months Ended
October 3, September 27, October 3, September 27,
2015 2014 2015 2014
GAAP net income per diluted share attributable to Masimo Corporation stockholders $ 0.36 $ 0.27 $ 1.10 $ 0.91
 
Non-GAAP adjustments
Constant currency F/X adjustments 0.03 0.11
Amortization of acquisition-related intangible assets 0.01 0.01 0.02 0.02
Litigation awards, damages and defense costs (0.14 )
Net tax impact of above items               0.05  
Total non-GAAP net income per diluted share adjustments   0.04     0.01     0.13     (0.07 )
 
Non-GAAP net income per diluted share attributable to Masimo Corporation stockholders $ 0.40   $ 0.28   $ 1.23   $ 0.84  

Source: Masimo

Masimo
Investor Contact:
Eli Kammerman
(949) 297-7077
ekammerman@masimo.com
or
Media Contact:
Irene Paigah
(858) 858-7001
irenap@masimo.com